Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study

References

• Domitrz I, Golicki D. Health-related quality of life in migraine: EQ-5D-5L-based study in routine clinical practice. J Clin Med. 2022;11(23):6925. doi:10.3390/jcm11236925
   Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd. Cephalalgia. 2018;38(1):1–211.
   PubMed Web of Science ®Google Scholar
• Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people’s life. J Headache Pain. 2019;20(1):41. doi:10.1186/s10194-019-0993-0
   PubMed Web of Science ®Google Scholar
• Raffaelli B, Neeb L, Reuter U. Monoclonal antibodies for the prevention of migraine. Expert opin biol ther. 2019;19(12):1307–1317. doi:10.1080/14712598.2019.1671350
   PubMed Web of Science ®Google Scholar
• Safiri S, Pourfathi H, Eagan A, et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022;163(2):e293–e309. doi:10.1097/j.pain.0000000000002275
   PubMed Web of Science ®Google Scholar
• Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clinics. 2019;37(4):631–649. doi:10.1016/j.ncl.2019.06.001
   PubMed Web of Science ®Google Scholar
• Aimovig™ (erenumab-aooe subcutaneous injection). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf. Accessed 3 January 2024.
   Google Scholar
• Emgality™ (galcanezumab-gnlm subcutaneous injection). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761063s000lbl.pdf. Accessed 3 January 2024
   Google Scholar
• Ajovy™ (fremanezumab-vfrm subcutaneous injection). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761089s000lbl.pdf. Accessed 3 January 2024
   Google Scholar
• American Headache Society. The American headache society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1–18. doi:10.1111/head.13456
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020;95(18):e2487–e2499. doi:10.1212/WNL.0000000000010600
   PubMed Web of Science ®Google Scholar
• Ford JH, Foster SA, Stauffer VL, Ruff DD, Aurora SK, Versijpt J. Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine. Patient Preference Adherence. 2018;12:2413–2424. doi:10.2147/PPA.S182563
   PubMed Web of Science ®Google Scholar
• Garland SG, Smith SM, Gums JG. Erenumab: a first-in-class monoclonal antibody for migraine prevention. Ann Pharmacother. 2019;53(9):933–939. doi:10.1177/1060028019835166
   PubMed Web of Science ®Google Scholar
• Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R. Treatment patterns for calcitonin gene-related peptide monoclonal antibodies including galcanezumab versus conventional preventive treatments for migraine: a retrospective US claims study. Patient Preference Adherence. 2022;16:821–839. doi:10.2147/PPA.S346660
   PubMed Web of Science ®Google Scholar
• Vandervorst F, Van Deun L, Van Dycke A, et al. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021;22(1):128. doi:10.1186/s10194-021-01335-2
   PubMed Web of Science ®Google Scholar
• Ailani J, Burch RC, Robbins MS. The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021–1039. doi:10.1111/head.14153
   PubMed Web of Science ®Google Scholar
• Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71(22):1821–1828. doi:10.1212/01.wnl.0000335946.53860.1d
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Olesen J, Bousser MG, et al. The International Classification of Headache Disorders, 2nd Edition (ICHD-II)--revision of criteria for 8.2 Medication-overuse headache. Cephalalgia. 2005;25(6):460–465. doi:10.1111/j.1468-2982.2005.00878.x
   PubMed Web of Science ®Google Scholar
• D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265–2281. doi:10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
   PubMed Web of Science ®Google Scholar
• Caponnetto V, Deodato M, Robotti M, et al. Comorbidities of primary headache disorders: a literature review with meta-analysis. J Headache Pain. 2021;22(1):71. doi:10.1186/s10194-021-01281-z
   PubMed Web of Science ®Google Scholar
• Ford JH, Jackson J, Milligan G, Cotton S, Ahl J, Aurora SK. A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache. 2017;57(10):1532–1544. doi:10.1111/head.13202
   PubMed Web of Science ®Google Scholar
• Hepp Z, Dodick DW, Varon SF, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470–485. doi:10.1177/0333102416678382
   PubMed Web of Science ®Google Scholar
• Ayer DW, Skljarevski V, Ford JH, Nyhuis AW, Lipton RB, Aurora SK. Measures of functioning in patients with episodic migraine: findings from a double-blind, randomized, placebo-controlled phase 2b trial with galcanezumab. Headache. 2018;58(8):1225–1235. doi:10.1111/head.13383
   PubMed Web of Science ®Google Scholar
• Buse DC, Gandhi SK, Cohen JM, et al. Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study. J Headache Pain. 2020;21(1):109. doi:10.1186/s10194-020-01177-4
   Web of Science ®Google Scholar
• Buse DC, Lipton RB, Hallström Y, et al. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia. 2018;38(10):1622–1631. doi:10.1177/0333102418789072
   PubMed Web of Science ®Google Scholar
• Ford J, Tassorelli C, Leroux E, et al. Changes in patient functioning and disability: results from a Phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN). Qual Life Res. 2021;30(1):105–115. doi:10.1007/s11136-020-02623-1
   PubMed Web of Science ®Google Scholar
• Lipton RB, Cohen JM, Gandhi SK, Yang R, Yeung PP, Buse DC. Effect of fremanezumab on quality of life and productivity in patients with chronic migraine. Neurology. 2020;95(7):e878–e888. doi:10.1212/WNL.0000000000010000
   PubMed Web of Science ®Google Scholar
• Lipton RB, Tepper SJ, Reuter U, et al. Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study. Neurology. 2019;92(19):e2250–e2260. doi:10.1212/WNL.0000000000007452
   PubMed Web of Science ®Google Scholar
• Hines DM, Shah S, Multani JK, Wade RL, Buse DC, Bensink M. Erenumab patient characteristics, medication adherence, and treatment patterns in the United States. Headache. 2021;61(4):590–602. doi:10.1111/head.14068
   PubMed Web of Science ®Google Scholar
• Ashina S. Identifying barriers to care-seeking, diagnosis, and preventive medication among those with migraine: results of the OVERCOME study. Headache. 2020;60:132–133.
   Web of Science ®Google Scholar
• Lipton RB, Serrano D, Holland S, Fanning KM, Reed ML, Buse DC. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache. 2013;53(1):81–92. doi:10.1111/j.1526-4610.2012.02265.x
   PubMed Web of Science ®Google Scholar